Compositions and methods for treating inflammation and photoreceptor cell degeneration in retinal degeneration patients

By developing a pharmaceutical composition containing a TPM1 inhibitor and adopting multiple delivery routes, the treatment problem of retinal degeneration is solved, and effective intervention and rescue of visual functions are achieved.

CN118987212APending Publication Date: 2024-11-22CENTRE FOR EYE AND VISION RESEARCH LIMITED +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410633562.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-29
Filing Date
2024-05-21
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat retinal degeneration, especially due to insufficient understanding of the molecular complexity of the disease and the lack of targeted treatment methods, which makes the progression of visual impairment difficult to control.

Method used

Develop a pharmaceutical composition containing a tropomyosin 1 (TPM1) inhibitor that inhibits TPM1 expression and activity through siRNA, antibodies or small molecule compounds and through different delivery routes such as corneal, blood-retinal barrier, intravitreal injection The drug is accurately delivered to the subretinal space by other means to treat retinal degeneration.

Benefits of technology

The pharmaceutical composition can effectively reduce neuroinflammatory, reverse photoreceptor degeneration, and save visual function, providing a comprehensive treatment plan for retinal degeneration, especially for age-related macular degeneration and retinal pigment degeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004850968050000011
    Figure HDA0004850968050000011
  • Figure HDA0004850968050000012
    Figure HDA0004850968050000012
  • Figure HDA0004850968050000021
    Figure HDA0004850968050000021
Patent Text Reader

Abstract

The invention relates to a composition and a method for treating inflammation and photoreceptor cell degeneration of a patient with retinal degeneration, and particularly provides a pharmaceutical composition for treating retinal degeneration, which comprises a tropomyosin 1 (TPM1) inhibitor and a pharmaceutically acceptable additive. The pharmaceutical composition can inhibit and / or reduce the expression and / or activity of TPM1 so as to treat diseases related to retinal degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 503,491 filed on May 21, 2023 and U.S. Non-Provisional Patent Application No. 18 / 592,423 filed on February 29, 2024, and the disclosures of which are incorporated herein by reference in their entirety.

[0003] Sequence Publication References

[0004] A sequence listing file named "2405484HK01_SequenceListing.xml" was submitted in the ST.26 XML file format, with a size of 21.7KB, created on May 21, 2024, and submitted on May 21, 2024, and its entire text is incorporated herein by reference. Technical Field

[0005] The present invention relates generally to the field of ophthalmology. More specifically, the present invention relates to a composition and method for treating inflammation and photoreceptor cell degeneration in patients with retinal degeneration. Background Art

[0006] Retinal degeneration (RD) is the leading cause of irreversible blindness worldwide, caused by factors such as genetic mutations, aging, environmental changes, or cell damage within the retina (Chang et al., 2002; Majidi et al., 2021; Wert et al., 2014). Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) represent two common forms of RD. AMD involves the degeneration of photoreceptor cells, particularly in the central macular region, leading to central vision loss. RP, on the other hand, encompasses a group of ocular diseases characterized by progressive photoreceptor degeneration that ultimately leads to partial or complete blindness. Vision loss has a significant impact on quality of life, manifested in reduced social interaction, decreased independence, and impaired mobility. Global estimates from 2015 indicate that approximately 253 million people suffer from visual impairment, with the prevalence of blindness and moderate to severe visual impairment (MSVI) continuing to increase (Ackland et al., 2017; Burton et al., 2021).

[0007] The mechanisms of photoreceptor degeneration in RD remain incompletely elucidated. Neuroinflammation has been implicated in the pathological progression of RD; however, the molecular complexity of the proinflammatory response in RD remains poorly understood, and specific treatments for RD are currently lacking. Despite attempts to rescue or slow retinal degeneration through clinical interventions and innovative treatments, a comprehensive approach to addressing this medical challenge remains elusive (Majidi et al., 2021).

[0008] Therefore, the present invention satisfies this need. Summary of the invention

[0009] The object of the present invention is to provide a method for solving the above technical problems.

[0010] Therefore, a first aspect of the present invention relates to a pharmaceutical composition for treating retinal degeneration, comprising a tropomyosin 1 (TPM1) inhibitor, wherein the TPM1 inhibitor inhibits and / or knocks down the expression and / or activity of TPM1.

[0011] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable additive.

[0012] In some embodiments, the TPM1 inhibitor is selected from siRNA, neutralizing antibodies or inhibitory small molecule compounds against TPM1, triggering receptor expressed on myeloid cells 2 (TREM2) or angiotensin (Vasn).

[0013] In some embodiments, the TPM1 inhibitor is selected from the group consisting of siRNAs in the following combinations:

[0014] siTPM1-1 (sense):

[0015] GAUGAACUGGACAAAUACUTT (SEQ ID NO: 17);

[0016] siTPM1-1 (antisense):

[0017] AGUAUUUGUCCAGUUCAUCTT (SEQ ID NO: 18);

[0018] siTPM1-2 (sense):

[0019] GAUCAGUAACCAAAUUGGATT(SEQ ID NO:19);

[0020] siTPM1-2 (antisense):

[0021] UCCAAUUUGGUUACUGAUCTT (SEQ ID NO: 20); or

[0022] siTPM1-3 (sense):

[0023] GAAAAGCAUUGAUGACUATT(SEQ ID NO:21);

[0024] siTPM1-3 (antisense):

[0025] UAAGUCAAUGCUUUUCTT (SEQ ID NO:22).

[0026] In some embodiments, the retinal degeneration is selected from age-related macular degeneration (AMD) or retinitis pigmentosa (RP).

[0027] In some embodiments, the pharmaceutically acceptable additives include excipients, stability additives, carriers, diluents, solubilizers.

[0028] In some embodiments, the pharmaceutical composition is formulated for administration for delivery through the cornea and / or the blood-retinal barrier to the subretinal space of a subject.

[0029] In a further embodiment, the administration form is selected from an immediate release form or a controlled release form.

[0030] In some embodiments, the pharmaceutical composition is formulated for delivery by a route selected from intravitreal injection, subretinal injection, or suprachoroidal injection.

[0031] In a further embodiment, the administration form is selected from an injection form, an eye drop form, an eye ointment form, a hydrogel form, an ultrasonic ocular drug delivery form, a drug-loaded contact lens form, a drug eluting implant form, a nanoparticle-mediated delivery form, an intravitreal gene therapy form, or an intravitreal microneedle form.

[0032] The second aspect of the present invention relates to a tropomyosin 1 (TPM1) inhibitor, which is selected from the following combination of siRNA:

[0033] siTPM1-1 (sense):

[0034] GAUGAACUGGACAAAUACUTT (SEQ ID NO: 17);

[0035] siTPM1-1 (antisense):

[0036] AGUAUUUGUCCAGUUCAUCTT (SEQ ID NO: 18);

[0037] siTPM1-2 (sense):

[0038] GAUCAGUAACCAAAUUGGATT(SEQ ID NO:19);

[0039] siTPM1-2 (antisense):

[0040] UCCAAUUUGGUUACUGAUCTT (SEQ ID NO: 20); or

[0041] siTPM1-3 (sense):

[0042] GAAAAGCAUUGAUGACUATT(SEQ ID NO:21);

[0043] siTPM1-3 (antisense):

[0044] UAAGUCAAUGCUUUUCTT (SEQ ID NO:22).

[0045] The third aspect of the present invention relates to the use of the pharmaceutical composition or TPM1 inhibitor in the preparation of a drug for treating neuroinflammation in a subject in need thereof, or for rescuing the visual function of a subject in need thereof.

[0046] In some embodiments, the medicament is for treating retinal degeneration in a subject in need thereof.

[0047] In some embodiments, the retinal degeneration is selected from age-related macular degeneration (AMD) or retinitis pigmentosa (RP).

[0048] In some embodiments, the subject in need thereof is a human subject.

[0049] In some embodiments, the drug is formulated for administration for delivery through the cornea and / or the blood-retinal barrier to the subretinal space of a subject.

[0050] In a further embodiment, the administration form is selected from an immediate release form or a controlled release form.

[0051] In some embodiments, the drug is formulated for delivery by a route selected from intravitreal injection, subretinal injection, or suprachoroidal injection.

[0052] In a further embodiment, the administration form is selected from an injection form, an eye drop form, an eye ointment form, a hydrogel form, an ultrasonic ocular drug delivery form, a drug-loaded contact lens form, a drug eluting implant form, a nanoparticle-mediated delivery form, an intravitreal gene therapy form, or an intravitreal microneedle form.

[0053] A fourth aspect of the present invention relates to a method of reducing neuroinflammation in a subject in need thereof or rescuing visual function in a subject in need thereof, comprising administering the above-mentioned pharmaceutical composition or TPM1 inhibitor to the subject. By administering the pharmaceutical composition or TPM1 inhibitor, the photoreceptor degeneration of the subject is reversed.

[0054] A fifth aspect of the present invention relates to a pharmaceutical composition or a TPM1 inhibitor as described above, for use in reducing neuroinflammation or rescuing visual function in a subject in need thereof.

[0055] In some embodiments, the pharmaceutical composition or TPM1 inhibitor is used to treat retinal degeneration in a subject in need thereof.

[0056] In a further embodiment, the retinal degeneration is selected from AMD or RP. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] This patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication in color will be provided by the Office upon request and payment of the necessary fee.

[0058] The embodiments of the present invention are described in more detail below with reference to the accompanying drawings.

[0059] Figures 1A-1C showed upregulation of TPM1 in the rd10 mouse RP model, where Figure 1A Western blot analysis of TPM1 in rd10 and C57BL / 6J mice at P16, P19, P22, and P25 is shown, and the quantitative results are shown in Figure 1B In Figure 1C Shown are qPCR analyses of Tpm1 in rd10 and C57BL / 6J mice at P16, P19, P22, and P25.

[0060] Figure 2A-2N showed that genetic knockdown of Tpm1 ameliorated inflammation and photoreceptor degeneration in rd10 mice, where Figures 2A-2F Tpm1 ( Figure 2A )、TNF-α( Figure 2B ), IL-1β( Figure 2C )、IL-6( Figure 2D )、COX-2( Figure 2E ) and iNOS( Figure 2F ) were analyzed by qPCR. n = 4 mice per group. Figure 2G Retinal sections stained with Iba-1 and CD68 antibodies are shown, and Figure 2H Shown is the quantification of microglial density in the outer nuclear layer (ONL) of rd10 and C57BL / 6J retinas treated with siTPM1 or siCTR at P25, where yellow arrows indicate resting microglia and white arrows indicate the migration of activated microglia into the ONL. Fig.2IDepicted are retinal sections stained with GFAP antibody in rd10 mice and C57BL / 6J mice treated with siTPM1 or siCTR at P25, with yellow arrows indicating resting astrocytes and white arrows indicating activated astrocytes and Müller cells in the retina. Figure 2J Shown is the quantification of GFAP immunofluorescence intensity in rd10 mice and C57BL / 6J mice treated with siTPM1 or siCTR at P25. Figure 2K TUNEL staining is shown (white arrows indicate TUNEL-positive cells in the retinal ONL). Figure 2L Depicted are quantification of TUNEL-positive cells in the ONL of rd10 retinas and C57BL / 6J retinas treated with siTPM1 or siCTR at P25. Figure 2M and Figure 2N Shown are scotopic and photopic electroretinogram (ERG) recordings of rd10 mice and C57BL / 6J mice treated with siTPM1 or siCTR at P25, respectively.

[0061] Figures 3A-3N describe that TPM1 overexpression exacerbates retinal glial responses and photoreceptor loss in rd10 mice, where Figures 3A-3F The expression of Tpm1 in rd10 mice treated with AAV-EGFP-TPM1 or AAV-EGFP at P25 is shown. Figure 3A )、TNF-α( Figure 3B ), IL-1β( Figure 3C )、IL-6( Figure 3D )、COX-2( Figure 3E ) and iNOS( Figure 3F ) by qPCR analysis. Figure 3G Retinal sections stained with Iba-1 antibody are shown (white arrows indicate the migration of activated microglia to the ONL), and Figure 3H Shown is the quantification of microglial density in the ONL of rd10 retinas treated with AAV-EGFP-TPM1 or AAV-EGFP at P25. Fig. 3I depicts retinal sections stained with GFAP (white arrows indicate activated astrocytes and Müller cells in the retina), and Figure 3J Shown is the quantification of GFAP immunofluorescence intensity in the retinas of rd10 mice treated with AAV-EGFP-TPM1 or AAV-EGFP at P25. Figure 3K TUNEL staining is described, and Figure 3LShown are TUNEL-positive cells (white arrows) in the retina of rd10 mice treated with AAV-EGFP-TPM1 or AAV-EGFP at P25. Figure 3M and Figure 3N ERG recordings from rd10 mice treated with AAV-EGFP-TPM1 or AAV-EGFP at P25 are shown, respectively.

[0062] Figures 4A-4X showed that TREM2 knockout downregulated TPM1 and suppressed retinal glial responses and photoreceptor degeneration in rd10 mice, where Figure 4A Depicted are qPCR analysis of TREM2 expression in rd10 and C57BL / 6J mice at P16, P19, P22, and P25. n = 4 and 6 mice for C57BL / 6J and rd10 db. Figure 4B Western blot analysis of TREM2 in rd10 and C57BL / 6J mice at P16, P19, P22, and P25 is shown, with quantitative results as shown in Figure 4C shown. Figure 4D-4H The expression of TREM2 at P25 was respectively depicted. - / - / rd10, rd10 and C57BL / 6J mice TNF-α ( Figure 4D ), IL-1β( Figure 4E )、IL-6( Figure 4F )、COX-2( Figure 4G ) and iNOS( Figure 4H ) by qPCR analysis. Fig. 4I shows the expression of TREM2 at P25 - / - Figure 3 Retinal whole mount samples stained with anti-Iba-1 and CD68 antibodies in the inner plexiform layer (IPL) and outer plexiform layer (OPL) of the retina of / rd10, rd10, and C57BL / 6J mice (yellow arrows indicate resting microglia, white arrows indicate activated microglia), where Iba-1 + Microglial cell number and Iba-1 + CD68 + Quantification of microglial numbers is presented in Figure 4J and Figure 4K middle. Figure 4L Retinal sections stained with Iba-1 and CD68 antibodies are depicted (white arrows indicate activated microglia migrating to the ONL). Figure 4M shows the expression of TREM2 at P25 - / - Quantification of microglial density in the retinal ONL of C57BL / 6J mice. Figure 4NRetinal sections stained with GFAP antibody are depicted (yellow arrows indicate resting astrocytes in the retina, white arrows indicate activated astrocytes and Müller cells), and Fig.4O Shows TREM2 at P25 - / - Quantification of GFAP immunofluorescence intensity in the retinas of C57BL / 6J / rd10, rd10, and C57BL / 6J mice. Figure 4P TUNEL staining is depicted, and Figure 4Q Shows TREM2 at P25 - / - Quantification of TUNEL-positive cells (white arrows) in the retinas of C57BL / 6J / rd10, rd10, and C57BL / 6J mice. Figure 4R Depicted is a retinal section stained with R / G opsin (yellow arrows show healthy cones in the retina, white arrows indicate abnormal cones), and Figure 4S Shows TREM2 at P25 - / - Quantification of OS / IS length in the retinas of C57BL / 6J / rd10, rd10, and C57BL / 6J mice. Figure 4T and Figure 4U Shows TREM2 at P25 - / - ERG recordings of C57BL / 6J, rd10, and TREM2 mice. - / - / rd10, n were 12, 15, and 18 mice, respectively. Figure 4V Depicts TREM2 at P25 - / - Western blot analysis of TPM1 and p-CREB / CREB in C57BL / 6J / rd10, rd10, and C57BL / 6J mice, and Figure 4W-4X Depicts TREM2 at P25 - / - / rd10, rd10 and C57BL / 6J mice TPM1( Figure 4W ) and p-CREB / CREB( Figure 4X ) quantification.

[0063] Figure 5A-5W TREM2 - / - Genetic overexpression of TPM1 in / rd10 mice increased inflammation and photoreceptor loss, in which Figures 5A-5H Figure 3 shows the expression of TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25. - / - / rd10 mice TPM1( Figure 5A )、TNF-α( Figure 5B ), IL-1β( Figure 5C )、IL-6( Figure 5D )、COX-2( Figure 5E )、iNOS( Fig. 5F )、IL-10( Figure 5G ) and IL-13( Figure 5H ) of the qPCR analysis results. Fig.5I Shown are TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 - / - Immunocytochemistry images of retinal whole mounts stained with Iba-1 in the retinal IPL and OPL of / rd10 mice. Figure 5J TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / - Quantification of Iba1+ microglia (white arrows) in the IPL and OPL of the retina of / rd10 mice. Figure 5K Retinal sections stained with Iba-1 are depicted (white arrows indicate the migration of activated microglia to the ONL), and Figure 5L TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / - Quantification of microglial density in the retinal ONL of rd10 / rd10 mice. Figure 5M Retinal sections stained with GFAP are depicted (white arrows indicate activated astrocytes and Müller cells in the retina), and Figure 5N TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / - Quantification of GFAP immunofluorescence intensity in the retina of / rd10 mice. Fig.5O TUNEL staining is shown. Figure 5P TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / - Quantification of TUNEL-positive cells (white arrows) in the retina of / rd10 mice. Figure 5Q Depicted is a retinal section stained with R / G opsin (white arrows indicate abnormal cones), and Figure 5R TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / - Quantification of OS / IS length in the retina of / rd10 mice. Figure 5S and Figure 5T TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 are shown, respectively. - / - a- and b-waves of ERG recordings from / rd10 mice. Figure 5U TREM2 treated with AAV-EGFP-TPM1 and AAV-EGFP at P25 is shown - / -Western blot analysis of TPM1 and p-CREB / CREB in / rd10 mice, with quantification results presented in Figure 5V (TPM1) and Figure 5W (p-CREB / CREB). DETAILED DESCRIPTION

[0064] In the following description, methods for treating retinal degeneration, etc. are listed as preferred embodiments. It is understood by those skilled in the art that these embodiments may be modified, including additions and / or substitutions, without departing from the scope and spirit of the invention. Specific details may be omitted so as not to obscure the invention; however, the present disclosure is intended to enable those skilled in the art to practice the teachings herein without undue experimentation.

[0065] According to a first aspect of the present invention, a pharmaceutical composition for treating retinal degeneration (a disease that significantly affects visual function) is provided. The composition includes a tropomyosin 1 (TPM1) inhibitor, which is a key component in regulating processes related to retinal degeneration. In order to ensure efficacy and safety, the pharmaceutical composition also includes various pharmaceutically acceptable additives, such as excipients, stability additives, carriers, diluents and solubilizers.

[0066] The term "TPM1 inhibitor" used herein refers to a substance that interferes with or inhibits the activity or function of the specific protein TPM1, which refers to the tropomyosin alpha-1 chain, a protein-coding gene. In the context of drug development, TPM1 inhibitors may be designed to regulate the biological effects of the tropomyosin alpha-1 chain to achieve therapeutic purposes. In some embodiments of the present invention, interference or inhibition of the activity or function of the specific protein TPM1 can be achieved by interference or inhibition at the nucleic acid level and / or protein level. In some embodiments of the present invention, interference or inhibition of the activity or function of TPM1 can be achieved by interference or inhibition of the activity or function of TPM1, triggering receptor 2 (TREM2) expressed on myeloid cells and / or angiotensin (Vasn) at the nucleic acid level and / or protein level. In some embodiments, interference or inhibition at the nucleic acid level can be achieved using small interfering RNA (siRNA) for TPM1, TREM2 and / or Vasn. Those skilled in the art are aware of the method of designing corresponding siRNA for a specific target and routinely verifying its interference activity. In some embodiments, the interference or inhibition of protein levels can be achieved using specific neutralizing antibodies for TPM1, TREM2 and / or Vasn. In some embodiments, the specific neutralizing antibody is a monoclonal neutralizing antibody. Those skilled in the art know how to prepare a method for a monoclonal neutralizing antibody for a specific antigen or epitope and routinely verify its neutralizing activity. In some embodiments, the monoclonal neutralizing antibody can be a commercially available monoclonal neutralizing antibody for TPM1, TREM2 or Vasn. In some embodiments, interference or inhibition of the activity or function of TPM1 can be achieved by a small molecule compound that interferes with or inhibits the activity or function of TPM1, TREM2 and / or Vasn. Those skilled in the art know how to screen for a specific target to interfere with or inhibit the method for a small molecule compound of its activity or function and routinely verify its activity.

[0067] One of the notable features of the pharmaceutical composition is its ability to inhibit and / or knock down the expression and / or activity of TPM1. By targeting TPM1, the pharmaceutical composition can interfere with the molecular processes that lead to retinal degeneration, thereby providing a potential therapeutic solution. This inhibition of TPM1 is achieved by adding a specific TPM1 inhibitor, which in one embodiment includes a triggering receptor expressed on myeloid cells 2 (TREM2) silencing agent.

[0068] In addition to the active drug ingredients, pharmaceutically acceptable additives also play an important role in the composition. Excipients contribute to the stability and bioavailability of the formulation, while carriers aid in the delivery of the active ingredient. Stability additives ensure the longevity of the composition, while solubilizers enhance the solubility of the active ingredient. This comprehensive formulation approach ensures that the pharmaceutical composition achieves its intended therapeutic effect precisely and efficiently.

[0069] The pharmaceutical composition is particularly useful for treating retinal degeneration, particularly age-related macular degeneration (AMD) and retinitis pigmentosa (RP). These diseases pose a significant challenge to vision and are one of the leading causes of visual impairment worldwide. By targeting TPM1, the pharmaceutical composition aims to address the molecular pathways associated with these diseases, thereby potentially slowing or stopping their progression.

[0070] In addition, the pharmaceutical composition is carefully formulated into an administration form that can be precisely delivered to the subretinal space of the subject. This strategic delivery helps to pass through the cornea and / or blood-retinal barrier, ensuring that the pharmaceutical composition reaches the specific anatomical site where its therapeutic effect is required. The administration form can be an immediate release form or a controlled release form, and the treatment mode can be flexibly selected according to the specific requirements of the subject and the nature of the retinal degeneration being treated.

[0071] There are several ways to deliver drugs to the subretinal space. For example, "intravitreal injection" is a common method of injecting drugs directly into the vitreous humor of the eye.

[0072] "Subretinal injection" is a surgical procedure that involves injecting a drug directly into the subretinal space. Briefly, the vitreous gel is removed and a bleb is formed beneath the retina, around the center of the retina, by injecting the drug composition.

[0073] "Suprachoroidal injection" refers to the delivery of the pharmaceutical composition into the suprachoroidal space behind the retina by office injection.

[0074] In addition to the common injection form, the pharmaceutical composition can also be formulated into various administration forms.

[0075] “Drug eluting implants,” such as delayed-release devices or drug-eluting micro / nanoparticles, can be surgically placed into the eye. These devices release drugs over an extended period of time and can be designed for targeted delivery under the retina.

[0076] "Nanoparticle-mediated delivery" means that the nanoparticles are engineered to encapsulate the drug and improve its bioavailability. Surface modification can be performed to enhance its affinity for the retina and facilitate subretinal delivery. In one embodiment, the drug composition is delivered by a nanoparticle or microemulsion drug delivery system, which enhances solubility and improves delivery efficiency or improves drug solubility and bioavailability by surface conjugation of active targeting agonists. In addition, the system also reduces drug toxicity, prolongs residence time and protects biological drugs from degradation. Another direction is to combine nanotechnology with other delivery systems, such as ultrasonic ocular drug delivery systems, drug-loaded contact lenses and hydrogels.

[0077] Ultrasound-mediated delivery uses ultrasound to enhance drug penetration into the retina. The application of ultrasound waves can temporarily disrupt the barrier, facilitating the entry of drugs into the subretinal space.

[0078] "Intravitreal gene therapy" can be delivered to specific cells in the retina, including cells in the subretinal space, by intravitreal injection. Viral vectors or nanoparticles can be used to deliver therapeutic genes.

[0079] "Electroporation" involves applying electrical pulses to cells, temporarily increasing cell membrane permeability. This technique has been used to enhance drug penetration into the retina, including the subretinal space.

[0080] The "intravitreal microneedle" is designed to penetrate the retina and deliver drugs to specific layers, including the subretinal space. Compared with traditional subretinal injections, this is a minimally invasive approach.

[0081] The choice of delivery method depends on factors such as the form of administration, target site, specific ocular condition, and desired duration of drug release.

[0082] In some embodiments, the administration forms include intravitreal injection forms, subretinal injection forms, eye drops forms, eye ointment forms, hydrogel forms, ultrasonic ocular drug delivery forms, drug-loaded contact lenses forms, drug eluting implant forms, nanoparticle-mediated delivery, intravitreal gene therapy forms, and intravitreal microneedle forms.

[0083] Drug formulation and delivery system are crucial for ophthalmic applications. The delivery of TPM1 inhibitors must cross the cornea and / or blood-retinal barrier and reach the retina and / or subretinal space. The delivery technology has the following characteristics: (1) simple and non-invasive administration; (2) efficient delivery system; (3) compatibility with ocular tissue; (4) targeting specific ocular diseases; and (5) controlled release system, which can retain active drugs in the retina for a long time (several months to several years).

[0084] Delayed release formulations of TPM1 inhibitors can be administered once a day or even less frequently. Delayed release formulations can be based on matrix technology. In this technology, the TPM1 inhibitor is embedded in an excipient to form a non-disintegrating core called a matrix. Diffusion of the TPM1 inhibitor occurs through the core.

[0085] The pulse release dosage form includes an immediate release dosage form containing a TPM1 inhibitor; and a delayed release dosage form containing a TPM1 inhibitor.

[0086] In one embodiment, a delayed release dosage form can be combined with an immediate release dosage form to provide a pulsatile release dosage form. The delayed release dosage form can be in the form of a core, which optionally contains an absorption enhancer and / or a water-swellable substance. The pulsatile release dosage form allows for control of plasma levels of a TPM1 inhibitor.

[0087] The term "immediate release" refers to a conventional or unmodified release form in which greater than or equal to about 75% of the active agent is released within two hours after administration, preferably within one hour after administration.

[0088] The term "controlled release" refers to a dosage form that controls or modifies the release of an active agent over a period of time. Controlled release may, for example, refer to a sustained, delayed, or pulsed release over a specific period of time. Alternatively, controlled release may mean that the release time of the active agent is longer than that of an immediate release dosage form, i.e., at least for several hours, e.g., more than four hours, preferably more than eight hours.

[0089] The term "delayed release" or "extended release" means that the active agent is released at such a rate that, after administration, the blood (e.g., plasma) level remains in the therapeutic range but below the toxic level for at least about 8 hours (preferably at least about 12 hours) at steady state. The term "steady state" means that the plasma level of a given active agent has been achieved and that the level is maintained at or above the minimum effective therapeutic level and below the minimum toxic plasma level of the given active agent at subsequent drug doses.

[0090] The term "delayed release" refers to the time delay before significant plasma levels of the active agent are reached. Delayed release formulations of active agents can avoid an initial burst of the active agent, or can be formulated to avoid release of the active agent in the eyeball or muscle layer, allowing absorption to occur in the retina.

[0091] A "pulsatile release" formulation may contain a combination of immediate release, sustained release and / or delayed release formulations in the same dosage form. A "semi-delayed release" formulation is a pulsatile release formulation in which an intermediate dose is provided immediately after administration and a further dose is provided several hours later.

[0092] According to a second aspect of the present invention, a method for reducing neuroinflammation in a subject suffering from neuroinflammation is provided. Specifically, the method involves administering the above-mentioned pharmaceutical composition to an individual in need of such intervention.

[0093] According to a third aspect of the present invention, a method for saving visual function is provided, wherein the above-mentioned pharmaceutical composition is administered to a subject with impaired vision. Specifically, the method not only saves visual function, but also reverses the degeneration of photoreceptors in the subject. This reversal marks a major advance in the treatment strategy of retinal degeneration, demonstrating the therapeutic effect of the pharmaceutical composition on the root cause of impaired vision.

[0094] According to a fourth aspect of the present invention, there is provided a pharmaceutical composition comprising a TPM1 inhibitor for use in treating retinal degeneration in a subject requiring such therapeutic intervention. The use provides a targeted approach to address the complexity associated with retinal degeneration, wherein TPM1 inhibition plays a key role in alleviating the progression of the disease. In a specific embodiment, the use is particularly effective in treating retinal degeneration, wherein retinal degeneration is determined to be AMD or RP. The pharmaceutical composition and its selected TPM1 inhibitor show efficacy in regulating the molecular pathways involved in these specific retinal degeneration conditions.

[0095] In particular, the pharmaceutical composition is capable of reducing neuroinflammation in subjects suffering from retinal degeneration, thereby preventing the progression of the disease. In addition, the pharmaceutical composition reverses photoreceptor degeneration and rescues the subject's visual function to cure or control retinal degeneration.

[0096] In summary, the present invention provides a comprehensive method and use of a pharmaceutical composition that provides a multifaceted approach to treating retinal degeneration, rescuing visual function, and reducing neuroinflammation for subjects in need thereof. The unique combination of a TPM1 inhibitor and a pharmaceutically acceptable additive makes the composition a promising therapeutic intervention for treating individuals affected by retinal degeneration.

[0097] In the context of describing the present invention (especially in the context of the following claims), the use of the terms "a", "an" and "the" and similar references should be interpreted as covering the singular and plural, unless otherwise specified herein or the context is clearly contradictory. The terms "include", "have", "include" and "contain" should be interpreted as open terms (i.e., meaning "including but not limited to"). Unless otherwise specified herein, the description of the numerical range herein is only intended to be a shorthand method for each individual value in the range as a separate reference, and each individual value is incorporated into the specification as if it is separately described. Unless otherwise specified herein or the context is clearly contradictory, all methods described herein can be performed in a suitable order. The use of any and all embodiments or exemplary language (such as "for example") provided herein is only intended to better illustrate the present invention, and unless otherwise stated, the scope of the present invention will not be limited. Any language in the specification should not be interpreted as indicating that any unclaimed element is essential to the practice of the present invention.

[0098] Example

[0099] Example 1. General method

[0100] Retinal immunoblotting

[0101] The retinas were washed with RIPA buffer (Abcam) or T-PER containing a protease and phosphatase inhibitor cocktail (Roche). TM Tissue protein extraction reagent (Invitrogen) was used for lysis on ice for 30 minutes. After centrifugation at 15,000 rpm for 15 minutes, the supernatant was transferred to a new sterile Eppendorf tube. TM Protein quantification was performed using the rapid gold BCA protein assay kit (Invitrogen). 20 μg of protein was loaded onto a 10% SDS-PAGE gel, and the gel was run at 80-100 V for 90 min, followed by transfer of the gel to a polyvinylidene difluoride membrane at 300 mA for 120 min. After blocking with 5% BSA for 1 h, the membrane carrying the protein was incubated overnight at 4 ° C with primary antibodies including rabbit anti-TPM1 (ABclonal, 1:1000), mouse anti-TREM2 (Santa Cruz, 1:500), rabbit anti-phospho-CREB (Ser133) (Cell Signaling Technology, 1:1000), rabbit anti-CREB (48H2) (Cell Signaling Technology, 1:1000), mouse anti-actin (ABclonal, 1:2000) and mouse anti-GAPDH (ABclonal, 1:2000). After washing three times with PBST, the membrane was incubated with secondary antibodies including goat anti-rabbit IgG and goat anti-mouse IgG conjugated with horseradish peroxidase (Invitrogen, 1:1000) for 2 h at room temperature. TM West Pico PLUS chemiluminescent substrate (Invitrogen) or ECL TM SelectWestern Blotting Detection Reagent(Amersham TM ) After incubation, the membrane containing the protein was evaluated using ChemiDoc Imaging Systems (Bio-rad, California, USA).

[0102] Immunocytochemistry and confocal imaging

[0103] After enucleation of the eyeball, the retina was separated from the vitreous and sclera with PBS, fixed with 4% paraformaldehyde (PFA) for 1 h, and then dehydrated with 30% sucrose at 4°C overnight. Some retinas were serially cut into 14 μm thick sections using a cryostat. After washing three times with PBS, the sections were incubated with Iba-1 (Wako, 1:500), CD68 (Bio-rad, 1:500) and GFAP (Dako, 1:500) in a blocking buffer containing 3% normal donkey serum (NDS), 1% bovine serum albumin (BSA) and 0.3% Triton X-100 in PBS (pH 7.4) at 4°C overnight. Secondary antibodies (including donkey anti-rabbit Alexa Fluor TM 488 (Invitrogen, 1:500), donkey anti-rat Alexa Fluor TM 568 (Invitrogen, 1:500) and donkey anti-rabbit AlexaFluor TM 594 (Invitrogen, 1:500)) was applied to the sections for 2 h, and then the sections were mounted with Dako fluorescent mounting medium. For whole-mounted retinas, two primary antibodies Iba-1 (Wako, 1:500) and CD68 (Bio-rad, 1:500) were applied in blocking buffer for 1 day, and then the secondary antibody donkey anti-rabbit Alexa Fluor TM 488 (Invitrogen, 1:500) and donkey anti-rat Alexa Fluor TM 568 (Invitrogen, 1:500) antibody was incubated for 2 h. Images were captured by a Zeiss LSM 800 upright confocal microscope (Zeiss, USA) with a pixel resolution of 1,024x 1,024 and a Plan-Apochromat 40x / 1.3 oil immersion lens or 20x / 0.8 lens. Z stack images were acquired with an interval of 0.5 μm. To quantify the fluorescence intensity of GFAP, three areas at 100 μm (center), 1 mm (middle) and 1.8 mm (periphery) from the optic nerve head were captured in each retinal section and analyzed using Image J software. To quantify microglia, four square sampling areas of 638.9 μm x 638.9 μm were photographed along the dorsoventral axis of the whole retinal sample at 200 μm and 1 mm from the optic nerve head on both sides, and Iba-1 was counted manually. + and CD68 + Iba-1 + The number of microglia.

[0104] Real-time quantitative PCR

[0105] Briefly, total RNA was extracted using TransZol Up Plus RNA Kit (TransGen, China) and First-Strand cDNA Synthesis SuperMix (TransGen, China) or PrimeScript1 st Strand cDNA Synthesis Kit (TaKaRa) was used for reverse transcription and then PerfectStart TM Green qPCRSuperMix (TransGen, China) or TB Premix Ex Taq TM II (Tli RNase H Plus) (TaKaRa) in QuantStudio TM 7Flex Real-Time PCR System (Applied Biosystems TM ) were used for real-time PCR. Gene-specific primers were as follows:

[0106] Tpm1(forward):

[0107] CTGAAGATGCTGACCGGAAGT(SEQ ID NO:1);

[0108] Tpm1(reverse):

[0109] TGGTTACTGATCTCTCTGCAAACTC(SEQ ID NO:2);

[0110] TNF-α(positive):

[0111] ATGGCCTCCCTCTCATCAGT(SEQ ID NO:3);

[0112] TNF-α(reverse):

[0113] TTTGCTACGACGTGGGCTAC(SEQ ID NO:4);

[0114] IL-1β(positive):

[0115] AATGCCACCTTTTGACAGTGATG(SEQ ID NO:5);

[0116] IL-1β(reverse):

[0117] GGAAGGTCCACGGGAAAGAC (SEQ ID NO: 6);

[0118] IL-6 (positive):

[0119] GGGACTGATGCTGGTGACAA(SEQ ID NO:7);

[0120] IL-6 (reverse):

[0121] AGCATTGGAAATTGGGGTAGGA (SEQ ID NO:8);

[0122] COX-2 (positive);

[0123] CTTCGGGAGCACAACAGAGT(SEQ ID NO:9);

[0124] COX-2 (reverse):

[0125] AAGTGGTAACCGCTCAGGTG (SEQ ID NO: 10);

[0126] Trem2(Forward):

[0127] CTTGCTGGAACCGTCACCAT(SEQ ID NO:11);

[0128] Trem2 (reverse):

[0129] CTTGATTCCTGGAGGTGCTGT(SEQ ID NO:12);

[0130] IL-10(positive):

[0131] GGTGAGAAGCTGAAGACCCT(SEQ ID NO:13);

[0132] IL-10 (reverse):

[0133] TCATTCATGGCCTTGTAGACACC(SEQ ID NO:14);

[0134] IL-13 (positive):

[0135] CCTGGATTCCCTGACCAACA (SEQ ID NO: 15); and

[0136] IL-13 (reverse):

[0137] ATTTTGGTATCGGGGAGGCT (SEQ ID NO: 16).

[0138] Example 2. TPM1 is upregulated in the rd10 mouse RP model

[0139] The expression of TPM1 was studied in the rd10 mouse model of retinitis pigmentosa (RP). The rd10 mouse was obtained from the Jackson Laboratory (Cat. No. 004297) and represents a well-established experimental model of human RP. These mice carry a mutation in the beta subunit of the rod-specific phosphodiesterase gene (PDE6β), which results in rod cell death at postnatal day 18 (P18) and complete loss of rod cells by P30. Notably, cone cell density in rd10 mice remains essentially normal until P25, when it declines to undetectable levels by 2-4 months of age. Given that mutations in the same gene have been found in patients with autosomal recessive RP, the rd10 mouse serves as a relevant model for studying human RP.

[0140] To investigate the role of TPM1 in TREM2-mediated inflammation in RP, TREM2 - / - Mice were crossed with rd10 mice to generate TREM2 - / - All mice were housed in a 12-h light / dark cycle with water and food available ad libitum and maintained in the Central Animal Facility of the Hong Kong Polytechnic University. All experimental procedures were approved by the Subcommittee on Animal Subjects Ethics Committee (ASESC) of the Hong Kong Polytechnic University and performed in accordance with the ARVO Statement on the Use of Animals.

[0141] To analyze the temporal expression of TPM1 during photoreceptor degeneration in rd10 mice, retinas were collected at P16 (pre-degeneration), P19 (early degeneration), P22, and P25 (mid-degeneration).

[0142] The results showed that compared with age-matched WT mice, TPM1 protein levels in rd10 mice continued to increase from P19 and were significantly elevated at P22 and P25 ( Figure 1A-1B This upregulation is consistent with transcriptome data ( Figure 1C and Figure 2A These findings suggest that TPM1 is intricately associated with the pathological progression of RP in the rd10 mouse model.

[0143] Example 3. TPM1 knockdown improves inflammation and photoreceptor degeneration in rd10 mice

[0144] To investigate the role of TPM1 in the degeneration of RP photoreceptors, TPM1 was knocked down by intravitreal injection of TPM1-specific siRNA into rd10 mice. Synbio Technologies (China) synthesized three siRNA pools targeting TPM1 (siTPM1) and negative siRNA, and the siRNA sequences are as follows:

[0145] siTPM1-1(sense):

[0146] GAUGAACUGGACAAAUACUTT (SEQ ID NO: 17);

[0147] siTPM1-1 (antisense):

[0148] AGUAUUUGUCCAGUUCAUCTT (SEQ ID NO: 18);

[0149] siTPM1-2 (sense):

[0150] GAUCAGUAACCAAAUUGGATT(SEQ ID NO:19);

[0151] siTPM1-2 (antisense):

[0152] UCCAAUUUGGUUACUGAUCTT(SEQ ID NO:20);

[0153] siTPM1-3 (sense):

[0154] GAAAAGCAUUGAUGACUATT(SEQ ID NO:21);

[0155] siTPM1-3 (antisense):

[0156] UAAGUCAAUGCUUUUCTT(SEQ ID NO:22);

[0157] Negative siRNA (sense):

[0158] UUCUCCGAACGUGUCACGUdTdT (SEQ ID NO: 23), a 3' modification with a terminal deoxynucleotidyl transferase recognition site; and

[0159] Negative siRNA (antisense):

[0160] ACGUGACACGUUCGGAGAAdTdT (SEQ ID NO: 24), with a 3' modification of a terminal deoxynucleotidyl transferase recognition site.

[0161] Briefly, the 846 bp TPM1 fragment (NM_001164255.1) starting from the start codon was subcloned into the vector p-YOE-PR006 (UBIGENE, China). This vector features a ubiquitous CAG promoter to drive TPM1 expression and enhanced green fluorescent protein (EGFP) expression, which was then used to create pCAG-mTPM1-EGFP and pCAG-EGFP (negative control). Subsequently, these constructs were packaged with AAV5 serotype (UBIGENE, China), and the AAV stock concentration was adjusted to 1×10 13 Genome copies / mL.

[0162] For intravitreal injection of siRNA, mice were anesthetized with a mixture of ketamine hydrochloride (100 mg / kg) and xylazine (20 mg / kg) and placed under a dissecting microscope. After topical application of 0.5% Alcaine, the sclera in the upper part of the nasal cavity was incised using a sterile sharp 31G needle. A glass pipette was then inserted into the incision and approximately 1 μl of siRNA solution was slowly injected into the vitreous. After injection, mice were placed on a heating pad until full recovery. Starting from P16, rd10 and TREM2 were injected every two days. - / - This procedure was performed three times for 10 / rd10 mice, and then the retinas were collected at P25.

[0163] Following photoreceptor degeneration in RP, mutant proteins such as PDE6β trigger an inflammatory response that further exacerbates the pathological progression of RP (Ferrari et al., 2011; Liu et al., 2022; Ortega and Jastrzebska, 2021). In fact, we show that proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (COX-2 and iNOS) are significantly elevated in rd10 retinas at P25 compared with age-matched WT retinas ( Figure 2B-2F ), indicating increased inflammation. However, TPM1 knockdown in rd10 retina significantly reduced the transcriptome levels of the proinflammatory cytokine IL-6 and chemokines COX-2 and iNOS compared with the siCTR-treated group ( Figure 2A and 2D -2F), suggesting that TPM1 may regulate inflammation in rd10 mice.

[0164] Studies have shown that microglial activation occurs concurrently with photoreceptor apoptosis, thereby promoting the progression of RP (Kaur and Singh, 2021; Ortega and Jastrzebska, 2021; Peng et al., 2014; Rashid et al., 2019). To explore microglial activation, immunohistochemistry was performed using antibodies against Iba-1 (a specific marker for microglia) and CD68 (a marker for activated microglia). It was found that more microglia in the rd10 retina at P25 were positive for CD68 compared to age-matched WT retinas and presented a morphological change from a branched appearance to an amoeboid shape ( Figure 2G-2H ), and activated microglia migrate from their normal location within the outer plexiform layer (IPL) into the outer nuclear layer (ONL) ( Figure 2G-2H ), indicating microglial activation. After TPM1-specific siRNA treatment in rd10 mice to knock down TPM1, the number of activated microglia migrating to the ONL at P25 was significantly reduced compared with the siCTR-treated group ( Figure 2G-2H ), suggesting that TPM1 regulates microglial activation during photoreceptor degeneration.

[0165] In healthy retinas, astrocytes are exclusively confined to the nerve fiber layer (NFL). In RP, photoreceptor loss triggers astrocyte and Müller cell activation, with increased GFAP immunoreactivity. Processes of reactive astrocytes become thicker, and many thickened astrocyte processes extend from their initial flattened NFL into the inner plexiform layer (IPL) (Fernández-Sánchez et al., 2015; Li et al., 2022a). Consistent with these observations, astrocytes were found to be significantly activated in rd10 retinas at P25 compared with age-matched WT retinas, and processes of activated astrocytes migrated to the IPL and even to the ONL ( Figure 2I-2J However, knockdown of TPM1 in rd10 mice suppressed activated astrocytes, reduced GFAP immunoreactivity, and fewer astrocyte processes extending into the IPL and ONL compared with the siCTR-treated group ( Figure 2I-2J ), suggesting that TPM1 may be involved in regulating astrocyte activation in rd10 mice. Together, these results suggest that elevated TPM1 in the rd10 retina contributes to neuroinflammation.

[0166] There is increasing evidence that activated microglia can phagocytose apoptotic photoreceptors, thereby exacerbating photoreceptor degeneration in RP (Guo et al., 2022; Hickman and Izzy, 2018; Rashid et al., 2019). Since the present invention demonstrates that TPM1 regulates microglial activation during photoreceptor degeneration in the rd10 retina, we next explored whether elevated TPM1 in rd10 would lead to photoreceptor death. Therefore, a terminal deoxynucleotidyl transferase (TdT)-mediated biotinylated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) assay was performed. The results showed that TUNEL-positive cells were significantly increased in the ONL of rd10 mice at P25 compared with age-matched WT mice ( Figure 2K-2L ), indicating photoreceptor death, which is consistent with previous studies (Murakami et al., 2013; Newton and Megaw, 2020; Sanges et al., 2006). However, knockdown of TPM1 after siTPM1 injection in rd10 mice significantly reduced TUNEL-positive cells compared with the siCTR-treated group ( Figure 2K-2L ), suggesting that TPM1 is involved in regulating photoreceptor survival in rd10 mice.

[0167] Given the role of TPM1 in neuroinflammation and photoreceptor loss in rd10, the effect of TPM1 on visual function during photoreceptor degeneration was further evaluated using electroretinogram (ERG) analysis. Briefly, mice were anesthetized with a mixture of ketamine hydrochloride (100 mg / kg) and xylazine (20 mg / kg) after overnight dark adaptation. Then, the pupils were dilated with 1% mydriatic (Alcon) and the eyes were treated with 3% hydroxypropyl methylcellulose lubricating gel solution in both corneas to keep them moist, after which ERG recordings were performed using the Celeris ERG system (Diagnosys, USA). First, the ERGs were recorded at 0.01, 0.1, 1, and 3 cd·s / m 2 Dark ERG was performed at different light intensities. 2 After 10 min of light adaptation at a background light intensity of 3 and 10 cd·s / m 2 Photopic ERGs were recorded at a light intensity of 10.1°. Ten scans were acquired for each light stimulus. The amplitude of the ERG Ga wave was measured as the distance between the baseline and the negative peak, and the amplitude of the b wave was calculated between the bottom of the a wave and the top of the highest curve.

[0168] The results showed that compared with age-matched WT mice, the amplitudes of a- and b-waves in rd10 mice at P25 decreased continuously with increasing light intensity ( Figure 2M-2N), indicating decreased function in rd10 mice. Interestingly, knockdown of TPM1 in rd10 mice counteracted the decrease in a- and b-wave amplitudes, especially at 3 cd·s / m when TPM1-specific siRNA was injected intravitreally into rd10 mice. 2 Light intensity under dark conditions ( Figure 2M-2N ), indicating that TPM1 promotes vision loss in rd10 mice.

[0169] Taken together, these results demonstrate that elevated TPM1 during photoreceptor degeneration is causative for inflammation, photoreceptor death, and visual loss in RP.

[0170] Example 4. TPM1 overexpression exacerbates retinal glial responses and photoreceptor loss in rd10 mice

[0171] To further explore the role of TPM1 in regulating inflammation and photoreceptor survival in the progression of RP, a CAG-mTPM1-EGFP plasmid driven by the ubiquitous CAG promoter was constructed to overexpress TPM1, and pCAG-mTPM1-EGFP and pCAG-EGFP (negative control) were packaged with AAV5 serotype (UBIGENE). AAV-EGFP-TPM1 was delivered to rd10 mice by subretinal injection. Briefly, pups at P1 or P2 were placed on ice for a few minutes for anesthesia. Then, an incision of approximately 1.5 mm was made along the closed palpebral fissure under a dissecting microscope using straight Vannas scissors or a scalpel, and the eyelids were subsequently pulled open with curved forceps to fully expose the eye for injection. About 0.4 μl of AAV-EGFP-TPM1 or AAV-EGFP was injected into the subretinal space using an angled glass pipette controlled by 4i (Eppendorf). After injection, the eyeball was gently pushed back behind the eyelid and into the orbit using curved forceps, and some erythromycin eye ointment was applied to the eyelid incision to avoid infection. Then, the pups were placed on a 37°C heating pad until they fully recovered.

[0172] As used herein, the term "subretinal space" refers to the space located between the neural retina and the retinal pigment epithelium (RPE).

[0173] By subretinal injection of AAV-EGFP-TPM1 into rd10 mice, TPM1 overexpression significantly increased the transcriptome levels of proinflammatory cytokines IL-1β and IL-6 and chemokine COX-2 compared with the AAV-EGFP treatment group ( Figures 3A-3F ), suggesting that TPM1 upregulation may exacerbate inflammation. In addition, TPM1 overexpression in rd10 retina significantly enhanced the migration of activated microglia, and more activated microglia migrated from the normal layer within the OPL to the ONL ( Figure 3G-3H ). At the same time, it was observed that elevated TPM1 enhanced astrocyte activation, and compared with the control group, activated astrocytes showed thicker processes and hypertrophy morphology, and more activated astrocyte processes extended into the ONL ( Figures 3I-3J Together, these results demonstrate that increased TPM1 in rd10 retinas enhances retinal glial responses.

[0174] In addition, terminal deoxynucleotidyl transferase (TdT)-mediated biotinylated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) assay was performed to detect apoptotic cells. Briefly, the sections were fixed with 4% PFA at 37°C for 15 min and then permeabilized with proteinase K at room temperature for 15 min. Then, the sections were incubated with TdT reaction mixture at 37°C for 1 h. After rinsing three times with PBS, the sections were incubated with Alexa Fluor TM 594-Picolyl Azide-based TUNEL reaction mixture and 10X Click-iT TM Plus TUNEL reaction buffer additive (Invitrogen) was incubated at 37°C for 30 min. After washing several times with 3% BSA in PBS, the slides were incubated with DAPI (Sigma) for 15-20 min and mounted with Dako fluorescent mounting medium. To quantify TUNEL-positive cells, three views of 100 μm (center), 1 mm (middle) and 1.8 mm (periphery) from the optic nerve head were captured in each retinal section, and TUNEL-positive cells were manually counted.

[0175] TUNEL assay showed that overexpression of TPM1 in rd10 mice by subretinal injection of AAV-EGFP-TPM1 increased the number of TUNEL-positive cells compared with the AAV-EGFP treated group ( Figure 3K-3L ), indicating that TPM1 elevation exacerbates photoreceptor death. ERG recordings showed that the scotopic b-wave amplitude was significantly reduced in the AAV-EGFP-TPM1-treated retina compared with that in the AAV-EGFP-treated rd10 mouse retina, especially at 3 cd·s / m 2 Light intensity ( Figure 3M-3N ), indicating that the increase of TPM1 in the retina of rd10 mice is associated with decreased vision.

[0176] Together, these results further validate that TPM1 may directly mediate neuroinflammation and photoreceptor apoptosis during photoreceptor degeneration in RP.

[0177] Example 5. TREM2 knockout downregulates TPM1 and inhibits retinal glial responses and photoreceptor degeneration in rd10 mice

[0178] Triggering receptor expressed on myeloid cells 2 (TREM2) is exclusively expressed by microglia and plays an important role in regulating CNS neuroinflammation ( Li and Zhang, 2018 ; Walter, 2016 ), and TPM1 mediates inflammation downstream of TREM2 through the PKA / CREB signaling pathway ( Li et al., 2022b ).

[0179] The present invention investigated the role of TREM2 in TPM1-regulated inflammation and photoreceptor death in RP and examined the temporal expression pattern of TREM2 during photoreceptor degeneration in a RP mouse model. The results showed that the transcriptome level of TREM2 in rd10 continuously increased with photoreceptor death ( Figure 4A ), and the protein level of TREM2 was also significantly increased in rd10 retinas compared with age-matched WT retinas at P22 and P25 ( Figure 4B-4C ), which suggests that elevated TREM2 may be involved in the pathological process of RP.

[0180] To further explore the role of TREM2 in RP, - / - Mice (Jackson Laboratory, Cat. No. 027197) were backcrossed with rd10 mice to generate TREM2 - / - Compared with age-matched rd10 mice, TREM2 knockout in rd10 mice at P25 significantly reduced the transcriptome levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6, and chemokines COX-2 and iNOS ( Figure 4D-4H ), suggesting that TREM2 deficiency can counteract the inflammation caused by photoreceptor degeneration in RP. In addition, TREM2 knockout in rd10 mice at P25 significantly reduced the number of Iba1+ microglia in both the IPL and OPL ( Figure 4I-4K ) and inhibited the migration of activated microglia to the ONL ( Figure 4L-4M ).

[0181] Similarly, we observed that TREM2 knockout in rd10 mice at P25 significantly inactivated astrocytes, with decreased GFAP immunoreactivity and thinner processes ( Figure 4N-4O ). Together, these results suggest that TREM2 deficiency in rd10 mice suppresses retinal glial responses. As a result of inflammation suppression, TREM2 knockout in rd10 mice at P25 reduced the number of TUNEL-positive cells compared with age-matched rd10 mice ( Figure 4P-4Q ) and partially rescued cone loss ( Figure 4R-4S ), suggesting that TREM2 deficiency may benefit photoreceptor survival in RP. Functionally, we found that TREM2 knockout in rd10 mice at P25 significantly increased the amplitude of the b-wave under scotopic conditions at different light intensities, especially at 1 and 3 cd·s / m 2 Light intensity ( Figure 4T-4U ), indicating that TREM2 deficiency in rd10 mice can slow down visual acuity decline.

[0182] It is known that activation of CREB signaling plays a role in suppressing inflammation, elevated TPM1 promotes inflammation, and TPM1 regulates CREB signaling when mediating inflammation. In addition, TPM1 mediates inflammation downstream of TREM2 through the PKA / CREB signaling pathway. Interestingly, in the present invention, TREM2 knockout in rd10 mice at P25 significantly reduced the protein level of TPM1 and increased the expression of phosphorylated CREB compared to age-matched rd10 mice ( Figure 4V-4X ), suggesting that TREM2 can regulate TPM1 / CREB signaling during photoreceptor degeneration in RP. Together, these findings suggest that TREM2 deficiency in rd10 mice can partially rescue photoreceptor degeneration by regulating the TPM1 / CREB signaling pathway.

[0183] Example 6. TREM2 - / - Genetic overexpression of TPM1 in / rd10 mice increases inflammation and photoreceptor loss

[0184] To further investigate the role of TPM1 in TREM2-mediated inflammation in RP, we injected AAV-EGFP-TPM1 subretinally into the TREM2-mediated inflammation pathway. - / - TPM1 was overexpressed in / rd10 mice. The results showed that compared with the control group treated with AAV-EGFP, TREM2 was upregulated at P25. - / - Overexpression of TPM1 in / rd10 mice significantly increased the transcriptome levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, and chemokines COX-2 and iNOS, and decreased the expression of anti-inflammatory cytokines IL-10 and IL-13 ( Figures 5A-5H ), indicating that elevated TPM1 exacerbates inflammation in the TREM2-deficient rd10 retina. - / - Overexpression of TPM1 in / rd10 mice increased the number of Iba1+ microglia in the IPL ( Figures 5I-5J ), and more activated microglia migrated to the ONL ( Figure 5K-5L). At the same time, compared with the AAV-EGFP-treated control group, TREM2 - / - TPM1 elevation in / rd10 mice significantly enhanced astrocyte activation, with increased GFAP immunoreactivity, thicker processes, and more astrocyte processes extending into the IPL and ONL ( Figure 5M-5N ). These results indicate that increased TPM1 in TREM2-deficient rd10 mice exacerbates retinal glial responses.

[0185] Furthermore, we observed that subretinal injection of AAV-EGFP-TPM1 increased the expression of TREM2 in the retina compared with AAV-EGFP-treated control retinas. - / - Overexpression of TPM1 in / rd10 retina significantly increased the number of TUNEL-positive cells ( Figure 5O-5P ) and reduced the number of cone cells ( Figure 5Q-5R ), indicating that elevated TPM1 in the TREM2-deficient rd10 retina exacerbates photoreceptor loss. ERG recordings revealed that TREM2 was upregulated at P25 compared with AAV-EGFP-treated control mice. - / - The increase of TPM1 in / rd10 mice significantly reduced the 3cd·s / m 2 The amplitudes of a-wave and b-wave under dark conditions of light intensity ( Figure 5S-5T ), indicating that elevated TPM1 in TREM2-deficient rd10 mice leads to functional decline.

[0186] In addition, TREM2 - / - Overexpression of TPM1 in / rd10 retina significantly suppressed the protein level of phosphorylated CREB ( Figure 5U-5W ), suggesting that elevated TPM1 in the TREM2-deficient rd10 retina inactivates CREB signaling. Together, these findings further confirm that TREM2 regulates the TPM1 / CREB signaling pathway to mediate inflammation and photoreceptor loss in RP.

[0187] To further explore the downstream signaling of TPM1 in regulating inflammation and photoreceptor death, label-free LC-MS / MS analysis was performed. Proteomic analysis showed that angiotensin (Vasn) is a molecule involved in TPM1-mediated neuroinflammation and photoreceptor death in RP. Knockdown or overexpression of Vasn affected the role of TPM1 in RP in a similar manner to TPM1 and TREM2 (data not shown).

[0188] Microglial-derived neuroinflammation contributes to many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia. TPM1 is an important regulator of proinflammatory genes in microglia, which can trigger changes in gene signatures in microglia, leading to a gradual transition from homeostatic microglia to disease-associated microglia and neuronal death in wild-type and RP retinas. Therefore, targeting TPM1 can potentially be used to combat various inflammation-related neurodegenerative diseases in the brain.

[0189] In summary, the present invention demonstrates that TPM1 is significantly elevated in rd10 mice (a RP model mouse). Gain or loss of TPM1 function in rd10 mice demonstrates that TPM1 directly regulates neuroinflammation and photoreceptor apoptosis during photoreceptor degeneration.

[0190] In addition, triggering receptor expressed on myeloid cells 2 (TREM2), which is specifically expressed on brain microglia, is involved in regulating inflammation in rd10 mice. TREM2 knockout in rd10 mice suppressed retinal glial response, inflammation, and visual acuity loss, while TPM1 overexpression enhanced neuroinflammation and photoreceptor cell death and visual function loss in TREM2-deficient rd10 retinas, suggesting that TPM1 is a potential target for combating RD progression.

[0191] The terms "approximately", "substantially", "substantially" and "about" as used herein are used to describe and explain minor changes. When used in conjunction with an event or condition, the term can refer to a situation where the event or condition occurs exactly, or it can refer to a situation where the event or condition occurs approximately. The term "approximately" used herein with respect to a given value or range generally means within a range of ±10%, ±5%, ±1% or ±0.5% of the given value or range. A range can be expressed from one endpoint to another or between two endpoints. Unless otherwise stated, all ranges disclosed in the present invention include endpoints. When referring to "substantially" the same numerical value or characteristic, the term can refer to a numerical value within ±10%, ±5%, ±1% or ±0.5% of the average value of the value.

[0192] The above description of the present invention has been presented for purposes of illustration and description only and is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations will be apparent to those skilled in the art.

[0193] The embodiments were chosen and described in order to best explain the principles of the invention and its practical application, thereby enabling others skilled in the art to understand the invention for various embodiments and with various modifications as are suited to the particular use contemplated.

[0194] References:

[0195] [1]Chang,B.,Hawes,N.L.,Hurd,R.E.,Davisson,M.T.,Nusinowitz,S.,andHeckenlively,J.R.(2002).Retinal degeneration mutants in the mouse.Visionresearch 42,517-525.

[0196] [2]Fernandez-Sanchez,L.,Lax,P.,Campello,L.,Pinilla,I.,and Cuenca,N.(2015).Astrocytes and Muller Cell Alterations During Retinal Degeneration ina Transgenic Rat Model of Retinitis Pigmentosa.Frontiers in cellularneuroscience9,484.

[0197] [3]Ferrari,S.,Di Iorio,E.,Barbaro,V.,Ponzin,D.,Sorrentino,F.S.,andParmeggiani,F.(2011).Retinitis pigmentosa:genes and diseasemechanisms.Current genomics 12,238-249.

[0198] [4]Gargini,C.,Terzibasi,E.,Mazzoni,F.,and Strettoi,E.(2007).Retinalorganization in the retinal degeneration 10(rd 10)mutant mouse:amorphological and ERG study.The Journal of comparative neurology 500,222-238.

[0199] [5]Guo,L.,Choi,S.,Bikkannavar,P.,and Cordeiro,M.F.(2022).Microglia:Key Players in Retinal Ageing and Neurodegeneration.Frontiers in cellularneuroscience 16,804782.

[0200] [6]Hickman,S.,and Izzy,S.(2018).Microglia in neurodegeneration.21,1359-1369.

[0201] [7]Kaur,G.,and Singh,N.K.(2021).The Role of Inflammation in RetinalNeurodegeneration and Degenerative Diseases.23.

[0202] [8]Li,J.T.,and Zhang,Y.(2018).TREM2 regulates innate immunity inAlzheimer*s disease.15,107.

[0203] [9]Li,R.,Liang,Y.,and Lin,B.(2022a).Accumulation of systematicTPM1mediates inflammation and neuronal remodeling by phosphorylating PKA andregulating the FABP5 / NF-kB signaling pathway in the retina of aged mice.21,el3566.

[0204]

[10] Li,R.,Zhang,J.,Wang,Q.,Cheng,M.,and Lin,B.(2022b).TPM1mediatesinflammation downstream of TREM2 via the PKA / CREB signaling pathway.Journalof neuroinflammation 19,257.

[0205]

[11] Liu,W.,Liu,S.,Li,P.,and Yao,K.(2022).Retinitis Pigmentosa:Progress in Molecular Pathology and Biotherapeutical Strategies.23.

[0206]

[12] Murakami,Y.,Notomi,S.,Hisatomi,T.,Nakazawa,T.,Ishibashi,T.,Miller,J.W.,and Vavvas,D.G.(2013).Photoreceptor cell death and rescue inretinal detachment and degenerations.Progress in retinal and eye research 37,114-140.

[13] Newton,F.,and Megaw,R.(2020).Mechanisms of Photoreceptor Death inRetinitis Pigmentosa.11.

[0207]

[14] Ortega,J.T.,and Jastrzebska,B.(2021).Neuroinflammation as aTherapeutic Target in Retinitis Pigmentosa and Quercetin as Its PotentialModulator.13.

[0208]

[15] Peng,B.,Xiao,J.,Wang,K.,So,K.F.,Tipoe,G.L.,and Lin,B.(2014).Suppression of microglial activation is neuroprotective in a mouse model ofhuman retinitis pigmentosa.The Journal of neuroscience:the official journalof the Society for Neuroscience 34,8139-8150.

[0209]

[16] Rashid,K.,Akhtar-Schaefer,I.,and Langmann,T.(2019).Microglia inRetinal Degeneration.Frontiers in immunology 10,1975.

[0210]

[17] Sanges,D.,Comitato,A.,Tammaro,R.,and Mango,V.(2006).Apoptosis inretinal degeneration involves cross-talk between apoptosis-inducing factor(AIF)and caspase-12 and is blocked by calpain inhibitors.Proceedings of theNational Academy of Sciences of the United States of America 103,17366-17371.

[0211]

[18] Walter,J.(2016).The Triggering Receptor Expressed on MyeloidCells 2:A Molecular Link of Neuroinflammation and NeurodegenerativeDiseases.The Journal of biological chemistry 291,4334-4341.

[0212]

[19] Wang,H.,Xu,J.,Lazarovici,P.,Quirion,R.,and Zheng,W.(2018).cAMPResponse Element-Binding Protein(CREB):A Possible Signaling Molecule Link inthe Pathophysiology of Schizophrenia.Frontiers in molecular neuroscience 11,255.

[0213]

[20] Wen,AY,Sakamoto,KM,and Miller,LS(2010).The role of thetranscription factor CREB in immune function.Journal of immunology(Baltimore,Md:1950)185,6413-6419.

[0214]

[21] Wert,KJ,Skeie,JM,Davis,RJ,Tsang,SH,&Mahajan,VB(2012).Subretinal injection of gene therapy vectors and stem cells in the perinatalmouse eye.J Vis Exp(69).doi:10.3791 / 4286

[0215]

[22] Xiong, W., MacColl Garfinkel, AE, Li, Y., Benowitz, LI, & Cepko, CL (2015). NRF2 promotes neuronal survival in neurodegeneration and acute nervedamage. J Clin Invest, 125(4),1433-1445.doi:10.1172 / jci79735

[0216] The above references are incorporated herein by reference in their entirety.

Claims

1. A pharmaceutical composition for treating retinal degeneration, comprising a tropomyosin 1 (TPM1) inhibitor, wherein the TPM1 inhibitor inhibits and / or knocks down the expression and / or activity of TPM1.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a pharmaceutically acceptable additive.

3. The pharmaceutical composition according to claim 1 or 2, wherein the TPM1 inhibitor is selected from siRNA, neutralizing antibodies or inhibitory small molecule compounds against TPM1, triggering receptor expressed on myeloid cells 2 (TREM2) or angiotensin (Vasn).

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the TPM1 inhibitor is selected from the following combinations of siRNA: siTPM1-1 (sense): GAUGAACUGGACAAAUACUTT (SEQ ID NO: 17); siTPM1-1 (antisense): AGUAUUUGUCCAGUUCAUCTT (SEQ ID NO: 18); siTPM1-2 (sense): GAUCAGUAACCAAAUUGGATT(SEQ ID NO:19); siTPM1-2 (antisense): UCCAAUUUGGUUACUGAUCTT (SEQ ID NO: 20); or siTPM1-3 (sense): GAAAAGCAUUGAUGACUATT(SEQ ID NO:21); siTPM1-3 (antisense): UAAGUCAAUGCUUUUCTT (SEQ ID NO:22).

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the retinal degeneration is selected from age-related macular degeneration (AMD) or retinitis pigmentosa (RP).

6. The pharmaceutical composition according to any one of claims 2 to 5, wherein the pharmaceutically acceptable additives include excipients, stability additives, carriers, diluents, and solubilizers.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the pharmaceutical composition is formulated for administration for delivery to the subretinal space of a subject through the cornea and / or the blood-retinal barrier.

8. The pharmaceutical composition according to claim 7, wherein the administration form is selected from an immediate release form or a controlled release form.

9. The pharmaceutical composition according to claim 7 or 8, wherein the pharmaceutical composition is formulated for delivery by a route selected from intravitreal injection, subretinal injection or suprachoroidal injection.

10. The pharmaceutical composition according to any one of claims 7 to 9, wherein the administration form is selected from an injection form, an eye drop form, an eye ointment form, a hydrogel form, an ultrasonic ocular drug delivery form, a drug-loaded contact lens form, a drug eluting implant form, a nanoparticle-mediated delivery form, an intravitreal gene therapy form, or an intravitreal microneedle form.

11. A tropomyosin 1 (TPM1) inhibitor, which is selected from the following combinations of siRNA: siTPM1-1 (sense): GAUGAACUGGACAAAUACUTT (SEQ ID NO: 17); siTPM1-1 (antisense): AGUAUUUGUCCAGUUCAUCTT (SEQ ID NO: 18); siTPM1-2 (sense): GAUCAGUAACCAAAUUGGATT(SEQ ID NO:19); siTPM1-2 (antisense): UCCAAUUUGGUUACUGAUCTT (SEQ ID NO: 20); or siTPM1-3 (sense): GAAAAGCAUUGAUGACUATT(SEQ ID NO:21); siTPM1-3 (antisense): UAAGUCAAUGCUUUUCTT (SEQ ID NO:22).

12. Use of the pharmaceutical composition according to any one of claims 1 to 10 or the TPM1 inhibitor according to claim 11 in the preparation of a medicament for treating neuroinflammation in a subject in need thereof, or for rescuing the visual function of a subject in need thereof.

13. The use according to claim 12, wherein the medicament is for treating retinal degeneration in a subject in need thereof.

14. Use according to claim 13, wherein the retinal degeneration is selected from age-related macular degeneration (AMD) or retinitis pigmentosa (RP).

15. The use according to any one of claims 12 to 14, wherein the subject in need is a human subject.

16. The use according to any one of claims 12 to 15, wherein the drug is formulated for administration for delivery through the cornea and / or the blood-retinal barrier to the subretinal space of a subject.

17. The use according to claim 16, wherein the administration form is selected from an immediate release form or a controlled release form.

18. The use according to any one of claims 12 to 17, wherein the drug is formulated for delivery by a route selected from intravitreal injection, subretinal injection or suprachoroidal injection.

19. The use according to any one of claims 16 to 18, wherein the administration form is selected from an injection form, an eye drop form, an eye ointment form, a hydrogel form, an ultrasonic ocular drug delivery form, a drug-loaded contact lens form, a drug eluting implant form, a nanoparticle-mediated delivery form, an intravitreal gene therapy form, or an intravitreal microneedle form.

Citation Information

Cited By

  • Application of TPM1 in treatment of wet age-related macular degeneration

    CN121243398A

  • Application of TPM1 in the treatment of wet age-related macular degeneration

    CN121243398B